I plan to pursue several aspects of the work in my laboratory that have been supported by this project grant in the area of the biochemistry and molecular genetics of lysosomal acid hydrolases. Two genes coding for lysosomal proteins are to be studied; GM1 beta-galactosidase and the sphingolipid activator proteins (SAPS). Abnormalities in these genes result in distinct neurological disorders, -- GM1-gangliosidosis/ Morquio B disease (acid beta-galactosidase deficiency), metachromatic leukodystrophy-like and Gaucher-like syndromes-(SAP-1 and SAP-2 deficiencies respectively), and a unique pleomorphic syndrome (total SAP deficiency). Human cDNAs and the genes coding for other proteins in the above list have been cloned. In addition, we have also cloned the cDNA and the gene for the mouse GM1 beta-galactosidase. Research projects proposed include: (1) Cloning and characterization of mouse cDNA and the gene coding for the sphingolipid activator proteins (SAPs), (2) Functions of the translation products of the SAP gene, (3) Exploration of structure/function relationship of SAPs and GM1 beta-galactosidase, (4) Transgenic production of a mouse model of total SAP deficiency and GM1- gangliosidosis (GM1 beta-galactosidase deficiency) by the homologous recombination technology, and (5) Continuing identification of mutations in patients who suffer from the disorders due to defects in the above listed genes, and attempts at genotype/phenotype correlations through naturally-occurring mutations, site-directed mutagenesis, computer- assisted molecular modeling and expression systems. Standard methodologies include cDNA and genomic library construction, screening, the polymerase chain reaction, sequencing, allele-specific oligonucleotide screening, and transient functional expression in COS I cells. Isolation and characterization of the cDNA and the gene coding for the mouse SAPS will be accomplished through the expected homology between the human and mouse genes, as we have successfully done for cloning the mouse acid beta-galactosidase. Physiological functions of the SAP-gene products will be evaluated with metabolic loading of potential substrates in vivo and also in culture systems. The normal clones will be over-expressed and purified so that we can obtain milligram quantities of these proteins for subsequent biochemical experiments. The studies of the structure/function relationship of these proteins will extensively utilize site-directed mutagenesis based on the knowledge gained from naturally-occurring mutations and their enzymological properties coupled with information from computerized molecular modeling. The transgenic lines of mice will be generated by the homologous recombination technology using appropriate constructs of the mouse beta-galactosidase and SAP genes. Both naturally-occurring and mutagenesis-generated mutants will be evaluated functionally in the COS I cell and baculovirus systems. The new knowledge to be generated by this series of studies should contribute to our eventual understanding of the molecular pathogenesis of these serious genetic neurological disorders and to future attempts at the gene therapy of these disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS024289-08
Application #
3408722
Study Section
Neurology C Study Section (NEUC)
Project Start
1986-03-01
Project End
1999-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Suzuki, Kunihiko (2003) Globoid cell leukodystrophy (Krabbe's disease): update. J Child Neurol 18:595-603
Suzuki, K; Ezoe, T; Tohyama, J et al. (2003) Are animal models useful for understanding the pathophysiology of lysosomal storage disease? Acta Paediatr Suppl 92:54-62; discussion 45
Matsuda, J; Vanier, M T; Saito, Y et al. (2001) A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum Mol Genet 10:1191-9
Wu, Y P; McMahon, E J; Matsuda, J et al. (2001) Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol 60:1062-74
Matsuda, J; Vanier, M T; Saito, Y et al. (2001) Dramatic phenotypic improvement during pregnancy in a genetic leukodystrophy: estrogen appears to be a critical factor. Hum Mol Genet 10:2709-15
Tohyama, J; Matsuda, J; Suzuki, K (2001) Psychosine is as potent an inducer of cell death as C6-ceramide in cultured fibroblasts and in MOCH-1 cells. Neurochem Res 26:667-71
Morales, C R; Zhao, Q; El-Alfy, M et al. (2000) Targeted disruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J Androl 21:765-75
Tohyama, J; Vanier, M T; Suzuki, K et al. (2000) Paradoxical influence of acid beta-galactosidase gene dosage on phenotype of the twitcher mouse (genetic galactosylceramidase deficiency). Hum Mol Genet 9:1699-707
Ezoe, T; Vanier, M T; Oya, Y et al. (2000) Biochemistry and neuropathology of mice doubly deficient in synthesis and degradation of galactosylceramide. J Neurosci Res 59:170-8
Fujimoto, H; Tadano-Aritomi, K; Tokumasu, A et al. (2000) Requirement of seminolipid in spermatogenesis revealed by UDP-galactose: Ceramide galactosyltransferase-deficient mice. J Biol Chem 275:22623-6

Showing the most recent 10 out of 63 publications